enGene (NASDAQ:ENGN) Posts Quarterly Earnings Results, Beats Estimates By $0.91 EPS

enGene (NASDAQ:ENGN) posted its earnings results on Monday. The company reported $0.43 EPS for the quarter, beating the consensus estimate of ($0.48) by $0.91, FiscalAI reports. During the same period in the prior year, the business earned $0.51 EPS.

enGene Trading Down 1.1%

Shares of NASDAQ ENGN opened at $1.75 on Wednesday. enGene has a 52-week low of $1.40 and a 52-week high of $12.25. The firm has a 50 day moving average price of $4.21 and a two-hundred day moving average price of $7.15. The stock has a market cap of $117.22 million, a P/E ratio of -0.81 and a beta of -0.30. The company has a debt-to-equity ratio of 0.09, a quick ratio of 11.75 and a current ratio of 11.75.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cresset Asset Management LLC bought a new stake in enGene during the 2nd quarter worth approximately $36,000. Paloma Partners Management Co purchased a new stake in enGene during the 2nd quarter valued at $38,000. Raymond James Financial Inc. boosted its position in enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after buying an additional 7,932 shares during the period. Jump Financial LLC bought a new position in enGene in the 4th quarter worth $121,000. Finally, Millennium Management LLC raised its holdings in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after purchasing an additional 7,472 shares in the last quarter. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on ENGN shares. WBB Securities began coverage on shares of enGene in a research note on Monday, April 13th. They issued a “buy” rating and a $21.50 price target on the stock. Wells Fargo & Company reissued an “equal weight” rating and issued a $2.00 price target (down from $25.00) on shares of enGene in a research report on Friday, May 8th. Citizens Jmp lowered shares of enGene from an “outperform” rating to a “market perform” rating in a report on Friday, May 8th. Wall Street Zen lowered shares of enGene from a “hold” rating to a “sell” rating in a report on Saturday, April 18th. Finally, Raymond James Financial cut shares of enGene from a “strong-buy” rating to an “outperform” rating and set a $4.00 price target on the stock. in a research report on Friday, May 8th. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, enGene has a consensus rating of “Hold” and an average target price of $12.50.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.